SML3182

Eltrombopag

≥98% (HPLC)

• 別名: (Z)-3′-(2-(1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2′-hydroxybiphenyl-3-carboxylic acid, 3′-[(2Z)-2-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid, SB 497115, SB-497115, SB497115
• 実験式（ヒル表記法）: C₂₅H₂₂N₄O₄
• CAS番号: 496775-61-2
• 分子量: 442.47
• MDL番号: MFCD20926253
• UNSPSCコード: 12352200
• NACRES: NA.77

特性

• 品質水準: 100
• アッセイ: ≥98% (HPLC)
• 形状: powder
• 色: faint yellow to dark orange
• 溶解性: DMSO: 2 mg/mL, clear
• 保管温度: 2-8°C
• SMILES記法: OC1=C(C=CC=C1N/N=C2C(C)=NN(C/2=O)C3=CC(C)=C(C=C3)C)C4=CC=CC(C(O)=O)=C4

詳細

生物化学的／生理学的作用

Eltrombopag is an orally active nonpeptide thrombopoietin receptor (TpoR) agonist that selectively induces STAT activation and proliferation (EC50 = 270 & 30 nM, respectively) of hToR-transfected, but not non-transfected, BAF3 cells. Eltrombopag increases the differentiation of primary human CD34(+) bone marrow cells into CD41(+) megakaryocytes ex vivo (EC50 = 100 nM) and exhibits thrombopoietic activity in chimpanzees in vivo (10 mg/kg/day p.o.).

安全性情報

• ピクトグラム: GHS08,GHS05,GHS07,GHS09
• シグナルワード: Danger
• 危険有害性情報: H302,H318,H373,H411
• 注意書き: P260 - P273 - P280 - P301 + P312 - P305 + P351 + P338 - P314
• 危険有害性の分類: Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - STOT RE 2
• 保管分類コード: 11 - Combustible Solids
• WGK: WGK 3
• 引火点(°F): Not applicable
• 引火点(℃): Not applicable